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Abstract: 
The inactivation of cytochrome P450 enzymes by cyclopropylamines has been attributed to a 
mechanism involving initial one-electron oxidation at nitrogen followed by scission of the cyclopropane 
ring leading to covalent modification of the enzyme. Herein we report that in liver microsomes N-
cyclopropylbenzylamine (1) and related compounds inactivate P450 to a large extent via formation of 
metabolic intermediate complexes (MICs) in which a nitroso metabolite coordinates tightly to the heme 
iron, thereby preventing turnover. MIC formation from 1 does not occur in reconstituted P450 systems 
with CYP2B1/2, 2C11 or 2E1, or in microsomes exposed to gentle heating to inactivate the flavin-
containing monooxygenase (FMO). In contrast, N-hydroxy-N-cyclopropylbenzylamine (3) and N-
benzylhydroxylamine (4) generate MICs much faster than 1 in both reconstituted and microsomal 
systems. MIC formation from nitrone 5 (PhCH=N(O)cPr) is somewhat faster than from 1, but very much 
faster than the hydrolysis of 5 to a primary hydroxylamine. Thus the major overall route from 1 to a 
P450 MIC complex would appear to involve FMO oxidation to 3, further oxidation by P450 and/or FMO 
to nitrone 5' (C2H4C=N(O)CH2Ph), hydrolysis to 4, and P450 oxidation to α-nitrosotoluene as the 
precursor to oxime 2 and the major MIC from 1. 
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Introduction 
 The time- and cofactor-dependent inactivation of cytochrome P450 enzymes by 
cyclopropylamines such as 1 has long been thought to occur via single electron transfer (SET) 
oxidation at nitrogen, leading to ring opening of the cyclopropane ring and covalent modification 
of the enzyme as shown in Figure 1 [1]. This mechanism is supported by direct observations of 
ring-opened products in chemical model systems [2-5], and in the oxidation of 
cyclopropylanilines by peroxidases [6-8].  While the formation of cinnamaldehyde as a 
metabolite of an N-(2-phenylcyclopropyl)amine has been reported, direct evidence for the 
formation of ring-opened metabolites of a simple N-cyclopropylamine has not been 
demonstrated for a P450 system.  On the contrary, P450 systems have shown only formation of 
cyclopropanone hydrate from the N-dealklylation of cyclopropylanilines [7].  N-
Cyclopropylanilines, however, do not inactivate P450, which leaves open the possibility that 
they are oxidized differently from aliphatic cyclopropylamines such as 1. 
 To address this question we undertook an investigation of the metabolism of 1 by rat liver 
microsomes.  The metabolites observed included benzylamine, benzaldehyde, benzyl alcohol, 
cyclopropylamine, cyclopropanone hydrate and benzaldoxime (structure 2 in Figure 2) [9].  The 
formation of oxime 2 as a metabolite of 1 was an unexpected but interesting observation.  Oxime 
metabolites of amines arise via N-oxidation leading to a C-nitroso species that tautomerizes to 
the oxime [10].  C-Nitroso intermediates can also form metabolic intermediate (MI) complexes 
via coordinate-covalent bonding from the nitrogen lone pair to the ferrous heme iron of P450 
enzymes [11-13].  This type of MI complex (MIC) is recognizable by a prominent absorption 
maximum at approximately 455 nm in the difference spectrum of incubation mixtures.  Since MI 
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complexes are generally quite robust, their formation constitutes a form of suicide inactivation of 
P450 activity.   
 In this report we provide evidence that MI complex formation is a significant contributor 
to the net loss of P450 activity observed upon incubation of rat liver microsomes with compound 
1 and NADPH.  We also characterize the mechanism of the process leading to MIC formation 
through studies with purified isozymes and through elucidation of structure-activity 
relationships. 
 
Materials and Methods 
 
Reagents and General Procedures 
 [7-14C]-Benzoic acid and sodium [14C]-formate were purchased from Moravek 
Biochemicals (Brea, CA) with specific activities of 53 and 56 Ci/mol, respectively.  [7-13C]-
Benzoic acid and sodium [13C]-formate were purchased from Cambridge Isotopes Laboratories, 
Inc. (Andover, MA).  Compounds 2, 4, 6–9 and cyclopropylamine were obtained from Aldrich 
(Milwaukee, WI).  NADPH, glucose-6-phosphate and glucose-6-phosphate dehydrogenase were 
purchased from Sigma (St. Louis, MO).  Aminopyrine was from Mallinckrodt Inc. (St. Louis, 
MO).  All other chemicals and reagents were of reagent grade or higher purity and were 
purchased from commercial suppliers. 
 Melting points were obtained using a Uni-melt capillary melting point apparatus and are 
uncorrected.  The 1H and 13C NMR spectra of the synthesized compounds were recorded on 
Bruker DRX 400 or DRX 500 spectrometers.  Analytical thin layer chromatography (TLC) was 
performed on Analtech Uniplate 250 µ silica gel plates with detection by UV and I2.  GC/EIMS 
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analyses were performed on an HP5890 Series II GC fitted with a DB-5 capillary column (0.26 
mm x 30 m, J & W Scientific, Folsom, CA) coupled to an HP5971A Mass Selective Detector.  
Data were collected in full scan mode (40–350 AMU, 0.77 scans/sec) and analyzed using an 
HP5970 ChemStation.  Samples were analyzed using the following oven temperature program:  
60 ºC for 3 min; 10 ºC/min to 250 ºC; hold at 250 ºC for 5 min.  UV-vis spectra were recorded 
using a Hitachi U-3010 spectrophotometer.  Radiochemical purity of [1'-14C]-1·HCl and [7-14C]-
1·HCl was assessed by HPLC using a Kromasil C4 column (5 µm, 4.6 x 150 mm) and an 
isocratic solvent system consisting of 15% acetonitrile in 100 mM NaClO4 (pH 2.25) at a flow 
rate of 1 mL/min.  Column effluent was passed through a UV detector (210 nm) in series with a 
Ramona radioactivity flow detector with a solid scintillant cell.  Data were collected on an SRI 
chromatography data system and analyzed using Peak Simple software. 
 
Chemistry 
 Compounds 1 [14, 15], 5 [16] and 13 [17] were prepared by literature procedures and 
gave 1H NMR and mp that agreed with those reported.  Compounds 10 [18], 11 [19] and 14 [17] 
were available from previous work in our laboratory [14] and were indistinguishable by 1H NMR 
and MS characterization from the previously reported preparations of these compounds. 
 
 N,N-Dibenzyl-[13C]-formamide.  To a 30 mL culture tube (2 x 10 cm) was added 
dibenzylamine·HCl (1.46 g, 6.25 mmol), sodium [13C]-formate (0.35 g, 5.00 mmol) and 15 mL 
of acetonitrile.  The tube was capped with a Teflon-lined screw cap and the contents stirred at 82 
ºC for 48 h.  The reaction was cooled to room temperature and diluted with ether (50 mL), and 
the resulting solution rinsed with 1 M HCl (3 x 25 mL).  The ether solution was then dried over 
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magnesium sulfate, filtered and the solvent removed in vacuo.  This yielded a pale yellow liquid 
that solidified upon standing to form a white solid (0.79 g, 70 % yield).  1H NMR (400 MHz, 
CDCl3) δ 4.26 (d, 2H, J = 5.23 Hz), 4.41 (d, 2H, J = 2.98 Hz), 7.17-7.21 (m, 4H), 7.26-7.40 (m, 
6H), 8.52 (d, 1H, J = 118.51 Hz).  13C NMR (100.6 MHz, CDCl3) δ 44.81, 50.47, 127.86, 
127.90, 128.34, 128.70, 128.89, 129.11, 135.76, 136.14, 136.06 (13C enriched carbon).  GC/MS:  
tR 19.8 min, m/z 226 [M+]. 
 N,N-Dibenzyl-[1'-13C]-cyclopropylamine.  In a 3-neck round bottom flask N,N-
dibenzyl-[13C]-formamide (0.50 g, 2.21 mmol) was dissolved in 10 mL of dry tetrahydrofuran 
and stirred vigorously under nitrogen.  Titanium isopropoxide (850 µL, 2.88 mmol) was added, 
followed by 2.20 mL of a 3.00 M solution of ethylmagnesium bromide in ether (6.60 mmol).  
Upon addition of the Grignard reagent, gas evolution could be seen and a yellow color formed.  
The mixture was heated for 15 min at 45 ºC and an additional 1.50 mL of 3.00 M 
ethylmagnesium bromide (4.50 mmol) was added, whereupon the reaction mixture became 
black.  The mixture was heated to 45 ºC for 15 min and then allowed to cool to room temperature 
and stir for 12 h.  The reaction was quenched by addition of 10 mL of saturated aqueous 
ammonium chloride and the mixture concentrated in vacuo, resulting in formation of a white 
precipitate.  After adding 15 mL of 1 M NaOH the resulting mixture of precipitate and solution 
was divided into two 50 mL culture tubes.  Each tube was then extracted with ether (2 x 25 mL 
each) with the aid of centrifugation.  The extracts were pooled, dried over magnesium sulfate, 
filtered and concentrated in vacuo giving a yellow liquid (0.46 g).  This material was then 
applied to a silica gel column wluted with 4:1 hexanes/ethyl acetate to obtain a mixture of N,N-
dibenzylcyclopropylamine and N,N-dibenzyl-3-pentylamine (0.16 g).  This material was then 
applied to a second silica gel column eluted with 2.5% ether in pentane to obtain 0.11 g of N,N-
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dibenzyl-[1'-13C]-cyclopropylamine as a clear colorless liquid (32% yield).  1H NMR (400 MHz, 
CDCl3) δ 0.30-0.41 (m, 4H), 1.81 (doublet of septets, 1H, J = 167.13 Hz), 3.67 (d, 4H, J = 4.34 
Hz), 7.23-7.50 (m, 10H).  13C NMR (100.6 MHz, CDCl3) δ 7.71, 7.87, 36.50 (13C enriched 
carbon), 58.43, 126.95, 128.17, 129.65, 138.98.  GC/MS:  tR 17.8 min, m/z 238 [M+]. 
  [1'-13C]-1·HCl.  To a 16 x 100 mm culture tube containing N,N-dibenzyl-[1'-13C]-
cyclopropylamine (0.10 g, 0.42 mmol) in 2 mL of dry 1,2-dichloroethane was added 1-
chloroethyl chloroformate (140 µL, 1.26 mmol).  The tube was then purged with nitrogen, sealed 
with a Teflon-lined screw cap and heated to 90 ºC for 16 h with stirring.  TLC showed the 
presence of starting material so additional 1-chloroethyl chloroformate (45.3 µL, 0.42 mmol) 
was added, and the reaction stirred an additional 5 h at 90 ºC prior to cooling and concentration 
in vacuo.  Methanol (2 mL) was added to the resulting brown solution was heated at 70 ºC for 30 
min.  Removal of solvent in vacuo gave 0.11 g of a brown viscous liquid that solidified upon 
standing.  This solid was then dissolved in a minimum volume of hot absolute ethanol, the 
solution cooled to room temperature and ether added to precipitate the desired product, [1'-13C]-
1·HCl, as a white crystalline solid (36 mg,  45% yield).  mp 157-159 ºC.  1H NMR (400 MHz, 
D2O) δ 0.81-0.93 (m, 4H), 2.74 (dm, 1H, J = 186.28 Hz), 4.33 (s, 2H), 7.50 (bs, 5H).  13C NMR 
(100.6 MHz, D2O) δ 3.31, 3.45, 29.99 (13C enriched carbon), 52.07, 129.54, 129.92, 130.23.  
GC/MS (as free base):  tR 9.6 min, m/z 148 [M+]. 
 [1'-14C]-1·HCl was prepared in 24% yield (after purification) by the above method [1'-
14C]-1·HCl using sodium [14C]-formate mixed with ordinary sodium formate to achieve a 
specific activity of 0.50 Ci/mol.  HPLC indicated a chemical and radiochemical purity ≥ 98%. 
 N-Cyclopropyl-[7-13C]-benzamide.  A solution of [7-13C]-benzoic acid (0.31 g, 2.50 
mmol) and 240 µL of oxalyl chloride (2.75 mmol) in 3 mL dry benzene was heated to 80 ºC for 
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5 h in a 10 mL culture tube with a Teflon-lined screw cap.  The resulting solution was cooled and 
added dropwise to a stirred solution of cyclopropylamine (0.52 mL, 7.50 mmol) in 3 mL of 
benzene with cooling to 0 ºC.  A white precipitate formed and the mixture was stirred at room 
temperature overnight.  The reaction mixture was then diluted with 10 mL of ether and washed 
with 1 M NaOH (2 x 5 mL) and 1 M HCl (2 x 5 mL).  The aqueous rinsings were back-extracted 
with ether (1 x 10 mL each) and the organic portions pooled, dried over magnesium sulfate and 
concentrated in vacuo giving 0.31 g of a pale yellow solid (76% yield).  1H NMR (400 MHz, 
CDCl3) δ 0.62-0.66 (m, 2H), 0.88-0.94 (m, 2H), 2.91-2.96 (octet, 1H, J = 3.51 Hz), 6.25 (s, 1H), 
3.80 (s, 3H), 7.42-7.46 (m, 2H), 7.49-7.53 (m, 1H), 7.74-7.77 (m, 2H).  13C NMR (100.6 MHz, 
CDCl3) δ 7.04, 23.32, 127.01, 128.75, 128.79, 131.70, 169.07 (13C enriched carbon).  GC/MS:  
tR 15.1 min, m/z 162 [M+]. 
  [7-13C]-1·HCl.  N-Cyclopropyl-[7-13C]-benzamide (0.31 g, 1.89 mmol) was added to 3 
mL of dry tetrahydrofuran in a three neck round bottom flask fitted with a nitrogen inlet and a 
condenser.  Under an atmosphere of nitrogen and with cooling to 0 ºC a 1 M solution of 
BH3·THF (11.7 mL, 11.71 mmol) was then added dropwise with stirring.  The solution was then 
heated to reflux for 3 h, at which time TLC showed the reaction to be complete.  The reaction 
was quenched by dropwise addition of 5 mL of 6 M HCl, and the tetrahydrofuran was removed 
in vacuo.  The mixture was adjusted to pH > 13 by addition of 4 M NaOH and extracted with 
ether (3 x 15 mL).  The extracts were pooled, dried over magnesium sulfate, filtered and 
concentrated in vacuo giving 0.16 g of a clear colorless liquid.  The liquid was then dissolved in 
10 mL of ether and bubbled with HCl gas.  The white precipitate that formed was collected by 
suction filtration and dissolved in a minimum volume of hot absolute ethanol, cooled to room 
temperature, and the product precipitated by addition of ether giving 0.15 g of white crystalline 
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solid (44% yield).  mp 155-156 ºC.  1H NMR (400 MHz, D2O) δ 0.80-0.93 (m, 4H), 2.69-2.75 
(m, 1H), 4.31 (d, 2H, J = 144.61 Hz) 7.47 (m, 5H).  13C NMR (100.6 MHz, D2O) δ 3.33, 29.95 
(13C enriched carbon), 52.03, 129.50, 129.54, 129.93, 130.19, 130.23.  GC/MS (as free base):  tR 
10.4 min, m/z 148 [M+]. 
 [7-14C]-1·HCl was prepared by the above method in 44% yield from [7-14C]-benzoic acid 
at a specific activity of 0.45 Ci/mol. HPLC indicated a chemical and radiochemical purity ≥ 
98%. 
 Compound 3 was prepared by lithium aluminum hydride reduction of nitrone 5 as 
described by Morgan and Beckett [20].  Briefly, N-cyclopropylbenzylidene nitrone (0.79 g) was 
dissolved in dry tetrahydrofuran and cooled under nitrogen to 0 ºC on ice.  Lithium aluminum 
hydride (0.75 g, 19.70 mmol in 3 mL dry tetrahydrofuran) was added dropwise with continuous 
cooling.  The mixture was stirred for 1 h at which time both TLC and GC/MS showed 
hydroxylamine 3 to be the major product (Rf 0.66, 1:1 ether/pentane.  tR 11.3 min).  The reaction 
was quenched by addition of 10 mL H2O resulting in formation of a white precipitate that was 
removed by suction filtration.  The filtrate was extracted with ether (4 x 50 mL) and the extracts 
pooled, dried over magnesium sulfate and concentrated under vacuum giving a viscous yellow-
orange liquid (0.43 g).  After silica gel chromatography using 1:1 ether/pentane as solvent 0.18 g 
of the desired product was obtained as a white solid (22% yield from 1 as a precursor to 5).  mp 
63-66 °C.  1H NMR (400 MHz, CDCl3) δ 0.60-0.64 (m, 4H), 2.36-2.41 (m, 1H), 4.02 (s, 2H), 
5.05 (broad s, 1H), 7.25-7.39 (m, 5H).  13C NMR (100.6 MHz, CDCl3) δ 6.71, 40.55, 64.57, 
127.51, 128.48, 129.72.  MS (CI, NH3):  m/z 164 [MH+]. 
 12·HCl was prepared from N,N-dibenzylacetamide using titanium isopropoxide and 
ethylmagnesium bromide as described by Chaplinski and de Meijere [21]. Debenzylation of the 
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resulting N,N-dibenzyl(1'-methyl)cyclopropylamine was achieved at room temperature utilizing 
atmospheric pressure hydrogenation over palladium on carbon catalyst in acidic methanol [22]. 
The crude reaction product was dissolved in hot absolute ethanol and precipitated with ether 
resulting in 60% yield of 12·HCl from the N,N-dibenzyl(1'-methyl)cyclopropylamine. The 1H 
NMR, 13C NMR, EIMS (as the free base) and mp of the product were in agreement with those 
previously reported [19]. 
 
 15·HCl.  Using the procedure of Chaplinski and de Meijere [21] 15•HCl was prepared 
from N-benzyl-N-methylformamide (derived from the reaction of N-benzyl-N-methylamine with 
ammonium formate) [23], titanium isopropoxide and ethylmagnesium bromide in 15% yield.  
The 1H NMR, 13C NMR and EIMS (as the free base) matched those reported for this compound 
prepared by another method [15]. 
 
Biochemical studies 
 Enzyme preparations.  Liver microsomes were prepared from untreated and 
phenobarbital-treated male Sprague-Dawley rats (UT- and PB-microsomes, respectively) 
following literature protocols [7, 24].  Isolation of CYP2B1/2 from PB-microsomes was 
performed as previously reported [25].  Plasmid EL2, constructed [26] to express the cDNA of 
CYP2C11 [27] in E. coli was kindly provided by Dr. M. A. Correia (with permission from Dr. T. 
Omura).  This plasmid was expressed, and the CYP2C11 isolated and purified as described [26].  
A culture of E. coli engineered to express CYP2E1 was kindly provided by Prof. F.P. 
Guengerich; the desired protein was isolated and purified as described [28].  CYP2C11 and 
CYP2B1/2 (0.5-1.0 nmol) were reconstituted with reductase (1.0-2.0 nmol) and DLPC (30 µg) 
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for 40 min at 0 ºC [7].  CYP2E1 (1.0 nmol) was reconstituted with reductase (3.0 nmol), 
cytochrome b5 (5.0 nmol) and DLPC (30 µg) for 40 min at 0 ºC [29].  A culture of C-1A E. coli 
cells engineered [30] to express rat NADPH-cytochromme P450 oxidoreductase was generously 
provided by Dr. C. B. Kasper; the protein was expressed and purified as described. 
 
 Determination of mechanism-based inactivation of cytochrome P450 by 1 and 2.  
Mechanism-based inactivation by was determined using a two-stage assay procedure.  P450 
inactivation in a primary incubation consisting of concentrated enzyme and inhibitor was 
subsequently assessed after dilution of an aliquot of the primary incubation into a secondary 
assay to measure remaining enzyme activity.  For the primary incubation PB-microsomes were 
diluted with 0.1 M potassium phosphate buffer, pH 7.6, (buffer A) to a protein concentration of 2 
mg/mL and kept on ice until use.  Stock solutions of 1  at concentrations of 2.5, 5.0, 12.5, 25.0 
and 50.0 mM were prepared by dissolving 1·HCl in buffer A.  Stock solutions of 2 at 
concentrations of 5.0, 12.5, 25.0 or 50.0 mM were prepared by dissolving 2 in acetonitrile.  
Incubations were conducted in 1.7 mL Eppendorf tubes to which were added 384 µL of 
microsome suspension and 8 µL of either buffer A, acetonitrile or a stock solution of 1 or 2.  The 
resulting mixtures were incubated in an oscillating water bath at 33 ºC for 3 min prior to 
inititiating the reaction by adding 8 µL of NADPH solution (50 mM in buffer A), bringing the 
final incubation volume to 400 µL.   
 For the second stage assays, tubes were prepared containing 75 µL of aminopyrine 
solution (20 mM in buffer A), 10 µL of NADPH solution (50 mM in buffer A), 3 µL of an 
NADPH regenerating system (0.3 units/µL glucose-6-phosphate dehydrogenase in 1 M glucose-
6-phosphate) and 362 µL of buffer A.   
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 At various times 50 µL aliquots of the primary incubation were withdrawn and added to a 
secondary assay tube (prewarmed to 33 ˚C) thereby achieving a final volume of 500 µL and a 
protein concentration of 0.2 mg/mL.  Secondary incubations were then incubated for an 
additional 10 min in an oscillating water bath at 33 ºC and quenched by addition of 250 µL each 
of 15% zinc sulfate and saturated aqueous barium hydroxide solution.  After centrifugation 
(20,800 x g for 10 min), 800 µL of the supernatant was removed and combined with 400 µL of 
Nash reagent [31] followed by heating at 60 ºC for 10 min.  The absorbance of each incubation 
sample was then measured at 415 nm versus a similarly treated buffer (blank) solution.  
Formaldehyde formation was quantified using a calibration curve prepared in a similar manner 
from standard solutions. 
 Measurement of absorption spectra of P450 metabolic intermediate (MI) complexes.  
Aliquots of a suspension of PB-microsomes, or a solution of a purified resonstituted P450 (final 
P450 concentration 0.5-1.0 µM unless otherwise noted) were transferred to matched sample and 
reference cuvettes (480 µL each).  Each cuvette then received 10 µL of a 50 mM solution of 
NADPH in buffer A followed by zeroing of the baseline between 400-500 nm.  Reaction was 
started by addition of 10 µL of 5 mM test compound (dissolved in buffer A or methanol) to the 
sample cuvette and 10 µL of solvent to the reference cuvette.  For determination of absorbtion 
maxima and the extent of MIC formation, spectral scans (400-500 nm) were acquired once every 
60 sec from 400-500 nm until the amplitude of the difference spectrum plateaued at a maximum 
value.  Kinetic scans were performed by monitoring absorbance at 455 nm for up to 30 min. 
 Heat-treatment of microsomes.  Individual 1 mL aliquots of diluted PB-microsomes (1 
mg protein/mL) in thin-walled glass test tubes were partly immersed in a water bath at 50 ºC, 
shaken for 90 sec, and then immediately cooled by immersion in ice water [32].  Inactivation of 
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FMO was assessed by monitoring the oxidation of thiobenzamide to thiobenzamide S-oxide 
using the method of Cashman and Hanzlik [33].  The effect of heat treatment on P450 activity 
was assessed using the APD assay described above. 
 
Results 
 Incubation of varying concentrations of 1 with rat liver microsomes and NADPH leads to  
a time-, concentration-, and cofactor-dependent loss of cytochrome P450 activity as assessed by 
the aminopyrine N-demethylase (APD) assay.  A replot of the reciprocals of the slopes of Figure 
3 vs. the reciprocals of inhibitor concentration [34] leads to the kinetic constants reported in 
Table 1.  As described in earlier literature, the loss of APD activity in microsomes incubated 
with 1 does not proceed to completion but instead plateaus with ca. 25-30% activity remaining 
[35-37].  This behavior can also be seen in the apparent curvature and leveling off of the bottom 
line in Figure 3. 
 When 1 is incubated with microsomes and NADPH a characteristic difference spectrum 
with a maximum at 455 nm appears and increases in amplitute with time (Figure 4A).  This 
spectrum is consistent with the formation of a P450 metabolic intermediate (MI) complex in 
which the ferrous heme iron is ligated by the nitrogen lone pair of a C-nitroso metabolite of an 
amine [12].  Such complexes are generally quite robust, but characteristically, oxidation of the 
iron to Fe(III) with ferricyanide leads to destruction of the complex and loss of the 455 nm 
absorption associated with the MIC chromophore, as shown in Figure 4B.  MI complexes have 
extinction coefficients in the difference spectrum (A490 - A455) of approximately 65 mM-1cm-1 
[10, 38].  Using this value one can estimate the fractional conversion of P450 to MI complex and 
compare that to the fractional loss of catalytic activity. For example, incubation of PB-
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microsomes with 1 mM 1 for 10 min at 33 ˚C results in conversion of 19% of total P450 to MI 
complex, but at the same time the loss of APD activity is ca. 60%.  On the other hand incubation 
of PB-microsomes with 0.1 mM 1 for 10 min at 33 ˚C results in conversion of 26% of total P450 
to MI complex but only 34% of the APD activity is lost.  Others have also noted that low 
concentrations of amine substrates are optimum for generating MI complexes, while higher 
concentrations actually generate less MIC [11, 12, 39].  The reasons for the unusual biphasic 
dependence of MIC formation on amine concentration are not clear, but this pattern is decidedly 
different from the concentration dependence of P450 inactivation by 1 (Figure 3).  The lack of 
direct correlation between MIC formation and loss of enzyme activity suggests that the P450 
isozyme(s) participating in MI complex formation are not identical to those contributing to APD 
activity (as discussed further below).  
 To investigate which isozymes of P450 give rise to MI complexes during the metabolism 
of 1 we turned to reconstituted systems with CYP2B1/2, the major isoforms in PB-microsomes, 
and with 2C11 and 2E1 which are constitutive isoforms in male rat liver [40].  To our surprise 
we observed no MIC formation from 1 with any of these reconstituted systems (Table 2).  This 
observation caused us to consider a potential role for the flavin-containing monooxygenase 
(FMO) in MI complex formation.  Since FMO enzymes are known to form secondary 
hydroxylamine metabolites from secondary amines like 1, we tested hydroxylamines 3 and 4  for 
MIC formation.  Both compounds gave rise to substantial MIC formation in both reconstituted 
systems and in microsomes, and compared to 1, the rates were much greater with 3 and 4 (Table 
2 and Figure 5A).  Interestingly, nitrone 5,  which is a potential FMO metabolite of 3, also gives 
rise to an MI complex in microsomes, although it hardly does so in reconstituted systems (Table 
2).  Some nitrones are easily hydrolyzed to hydroxylamines, but repetitive UV scans (200-450 
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nm) of solutions of 5 in the phosphate buffer used for microsomal incubations, with or without 
added microsomal protein, showed that 5 is unchanged for at least 2 hr at room temperature.  
Thus, MIC formation from 5 must involve a mechanism not requiring hydrolysis. 
 Further support for an obligatory role for FMO activity in MIC formation from 1 comes 
from experiments with heat treatment of microsomes.  FMO enzymes are very heat-labile in the 
absence of NADP(H) [41].  Thus microsomes heated briefly without NADPH added (50 ˚C for 
90 sec, then rapidly cooled to ≤ 37 ˚C) are unable to form a MI complex from 1 plus NADPH, 
yet they retain ≥ 90% of their original P450 activity, and they give a strong MI response (≥ 95% 
of control) when treated with NADPH and 4 (data not shown).  These observations suggest that 
the N-oxidation of 1 by FMO is an obligatory step toward the generation of the MIC derived 
from 1.   
 Additional insight into MIC formation from cyclopropylamines comes from results with 
analogs of 1, as shown in Table 2 and Figure 5B.  As noted in earlier SAR studies of microsomal 
P450 inactivation by 1, benzylamine and N-alkylbenzylamines do not inactivate P450 [35, 42], 
while N-cyclobutylbenzylamine (11) does so only weakly [19].  The current work shows that 
neither do any of these compounds give rise to MI complexes in PB-microsomes (Table 2).  
Adding a methyl group on C-1' of the cyclopropyl moiety (12) actually increases MIC formation 
slightly compared to 1 (Table 2 and Figure 5B).  On the other hand, results with compounds 13 
and 15 indicate that adding one methyl to the benzylic carbon of 1 significantly decreases the 
rate and extent of MIC formation, while adding two methyl groups blocks MIC formation 
entirely.  Finally, studies with 15 show that adding a methyl to the nitrogen of 1 results in a 
prominent lag period, after which MIC formation proceeds at the same rate as with 1 itself, 
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suggesting that 15 must first be N-demethylated to 1 by P450 and then oxidized to 3 by the FMO 
prior to forming an MI complex. 
 Although incubation of oxime 2 (100 µM) with PB-microsomes (1 mM NADPH, 25 ˚C, 
30 min) does not result in MIC formation, we tested the ability of 2 to inactivate P450 as a 
suicide substrate.  Figure 6 shows that under conditions capable of supporting P450 activity, 
oxime 2 does cause time-, concentration- and cofactor-dependent loss of APD activity in PB-
microsomes; the relevant kinetic parameters are given in Table 1.  Although the kinetic 
parameters for 2 are very similar to those for 1, oxime 2 is unlikely to contribute significantly to 
the inactivation of microsomal P450 observed with 1 because at a concentration of 1 mM, only 
20% of 1 is metabolized during a 60 minute incubation, and oxime 2 accounts for only 19% of 
the total metabolites formed.  Thus during a normal (10 min) assay for P450 inactivation or MIC 
formation, the concentration of 2 remains far too low for it to be an effective P450 inactivator, 
especially in the presence of a much higher concentration of 1. 
 
Discussion 
 The discovery of 1 as a suicide substrate for cytochrome P450 enzymes was based on the 
observation of time- and cofactor-dependent loss of the aminopyrine N-demethylase and p-
nitroanisole O-demethylase activites of PB rat liver microsomes [35, 42]. Results presented in 
Figure 3 confirm the time-dependence and also indicate the concentration dependence of the 
inactivation process.  They also confirm that as originally described, the inactivation of APD 
activity does not go to completion but rather levels off with ca. 25-30% of the original activity 
remaining.  In retrospect, we now know that as substrates, aminopyrine and p-nitroanisole are 
relatively non-selective among common P450 isoforms [43].  Thus there could be several 
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possible explanations for the observed incompleteness of the inactivation process.  One is that 1 
is moderately selective in inactivating some but not all of the P450 isoforms which metabolize 
aminopyrine and p-nitroanisole.  Another is that the catalytic activity of P450 enzymes 
covalently modified by reactive metabolites of 1 is decreased but not eliminated.  A third is that 
at longer incubation times, the FMO enzyme loses its activity due to thermal or other natural 
degradative processes, thus halting the N-oxidation of 1 that is apparently required, at least for 
MI complex formation, and possibly for P450 inactivation by other mechanisms as well.  Since 
any or all of the above scenarios could be operating in rat liver microsomes, the remainder of this 
discussion will be focussed primarily on the issue of MIC formation from 1. 
 The inactivation of P450 by 1 was first attributed to a putative electrophilic 
cyclopropylidene Schiff base metabolite formed by the classical hydrogen atom transfer (HAT) 
mechanism that was thought to be involved in numerous C-hydroxylation and  N- and O-
dealkylation reactions of P450 [35].  However, the observation that 12, the C-1' methyl 
derivative of 1, which can not form a cyclopropylidene Schiff base, was as effective a P450 
inactivator as 1, led to the proposal of the single electron transfer (SET) mechanism as a specific 
mechanism for the inactivation of P450 by cyclopropylamines (see Figure 1) [36, 37], and as a 
potentially general mechanism for N-dealkylation of amines.  While these mechanisms have 
been much studied and much debated for more than 20 years [44-48], the new observation of 
extensive P450 MIC formation from 1 provides an important alternative to the SET mechanism 
for at least a portion, and possibly a significant portion, of the observed inactivation of P450 by 1 
and related cyclopropylamines.   
 Formation of MICs from 1 can not account for all the loss of P450 activity, however.  For 
example, analog 14 inactivates P450 but does not form an MI complex.  In addition, the 
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percentage loss of P450 activity observed with 1 also greatly exceeds the percentage of P450 
converted to MI complex(es) in microsomes.  Since the available data can not rule out the 
possibility that this reflects extensive MI complex formation with a small subset of P450s that 
happen to make a major contribution to the oxidation of aminopyrine by PB-microsomes, further 
studies will be required to elucidate the contribution of individual P450 isoforms to both the loss 
of activity and the MIC formation observed in microsomes. 
 The conversion of a secondary amine to a C-nitroso compound, the presumed precursor 
of oxime 2 and the presumed ligand responsible for heme-based MI chromophore formation, 
requires a formal six-electron oxidation.  This process almost certainly occurs in three two-
electron steps as outlined in Figure 7 .  At the outset, either N-oxidation of 1 (step a) or alpha 
carbon oxidation of 1 (step g) are logical possibilities.  Although several studies indicate that 
P450 can N-hydroxylate some primary and secondary amines [49, 50], the observation that mild 
heating of microsomes abolishes MIC formation from 1 with little effect on P450 activity as 
assessed by APD activity argues strongly for the importance of FMO enzyme(s) in the formation 
of MI complexes from 1.  FMO involvement could occur at steps a, b, or e in Figure 7, but since 
FMO enzymes in rat liver generally do not N-oxidize primary amines [11, 41, 51, 52], and since 
benzylamine (6) and cyclopropylamine do not give rise to MIC formation, step i in Figure 7 is 
probably not significant.  On the other hand step g, which is likely to be catalyzed by P450 
enzymes, seems highly probable because benzaldehyde, cyclopropylamine, benzylamine and 
cyclopropanone hydrate are all formed during the microsomal metabolism of 1; none of these 
compounds, however, give rise to MICs in microsomes.   
 In agreement with earlier studies MIC formation from 3 or 4 occurs much more rapidly 
than from 1 (or from 12, 13 or 15), and MIC formation is generally faster and more extensive in 
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PB-microsomes than in UT-microsomes [11, 12, 39, 53].  Deuteration of the alpha carbon of 
amphetamine (18) results in a 1.8-fold increase in the rate of MIC formation, which probably 
reflects a primary kinetic deuterium isotope effect on the partitioning of the nitroso compound 
between oxime formation vs. MIC formation (Figure 7) [10].  Methyl substitution around the 
nitrogen also strongly affects MIC formation.  For example, N-hydroxyamphetamine (16) and N-
hydroxy-2-phenylethylamine (17) form MI complexes much faster than amphetamine, but 2-
phenylethylamine (19) does not form an MIC [12].  On the other hand neither phentermine (20) 
nor its N-hydroxy derivative, nor even the corresponding nitroso compound, form P450 MI 
complexes [10], probably for reasons of steric hindrance in the P450 active sites.  Methylation 
also influences MIC formation from congeners of 1 (Figure 5B).  For example 14, like 
phentermine (20), does not form an MI complex in PB-microsomes, but whereas adding a methyl 
group to 19 to make 18 confers MIC-forming ability, adding one or two methyl groups to the 
benzylic carbon of 1 decreases or abolishes MIC formation, respectively.  Finally, N-methylation 
of 1 delays the start of MIC formation, suggesting, as noted by others [11, 12], that tertiary 
amines must first be N-dealkylated to secondary amines en route to MIC formation. 
 The role of nitrone metabolites in MIC formation has never been fully elucidated.  
Nitrone metabolites of various amines have occasionally been reported in vivo and in vitro with 
microsomes and even reconstituted P450 systems [54, 55], but rarely are they observed as major 
metabolites, possibly because many nitrones are hydrolytically labile (steps c and d in Figure 7).  
Nitrone 5 is one of two conceivable nitrone metabolites of 1 (see Figure 8), but 5 is observed to 
be very stable in solution at pH 7.5, possibly because it is conjugated [55, 56].  The isomeric 
nitrone 5', however, would be quite electrophilic and reactive, like cyclopropanone itself, 
because of the sp2 carbon in the strained three-membered ring.  For this reason, and because 5' is 
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not stabilized by conjugation like 5, hydrolysis of 5' should occur quite readily.  This would 
release hydroxylamine 4, which is very efficient at forming MI complexes in microsomes and in 
reconstituted systems (Table 2).  That oxime 2 is a significant  metabolite of 1 (19% of total) 
further emphasizes the probable importance of the route through 5' to MIC formation. 
 Two major questions remain about the role of nitrone metabolites in MIC formation from 
1 (or 3).  First, why is exogenously introduced nitrone 5 such a sluggish precursor to MIC 
formation compared to exogenously introduced 3 or 4?  Second, given that hydrolysis of 15 is 
too slow to be involved in MIC formation, how does nitrone C-N bond cleavage occur?  It is 
possible, although not necessarily predictable, that the major route to MIC formation from 1 or 3 
is actually via 5' and not 5, and that exogenously introduced 5 undergoes a direct oxidative 
conversion to a nitroso ligand for MIC formation, thereby obviating the need for hydrolysis.  A 
potential mechanism for the direct oxidation of nitrone to nitroso is depicted in Figure 9.  There 
is now considerable evidence that the hydroperoxy-iron derivative of P450 can be a nucleophilic 
as well as electrophilic oxidant and oxygen atom transfer agent (for leading references see [57]).  
Nitrones are electrophilic; thus addition of an EnzFe(III)-O-O-H group to the nitrone sp2 carbon 
could lead to the bond rearrangements suggested in Figure 9.  This would provide a non-
hydrolytic mechanism for C-N bond cleavage, and would generate the putative nitroso MIC 
ligand directly in front of the heme iron.  One-electron reduction could then form the stable 
(ferrous) MIC complex shown in Figure 7.  Precedent for this suggestion can be found in a 
review by Lindeke [58] which suggested that a structure analogous to 21 (i.e., R = PhCH2-, R' = 
Ph, but with H replacing EnzFe) could undergo decomposition to form benzaldehyde, water and 
α-nitrosotoluene (PhCH2NO) as a precursor to benzaldoxime (2).  Further precedent comes from 
work of Sang et al. who showed that alkylhydroperoxy radicals (ROO•) add to the spin-trap 
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reagent C-phenyl-N-tert-butyl nitrone (PBN) to form unstable adducts resembling structure 21 
that decompose with C-N and O-O bond scission [59]. 
 In summary, the inactivation of cytochrome P450 enzymes by cyclopropylamines such as 
1 (and 14) may involve SET oxidation followed by ring opening and covalent modification of 
enzyme as suggested in Figure 1, but evidence presented above makes it clear that MIC 
formation occurs and can potentially account for a significant fraction of the P450 inactivation 
by 1 and analogs 3, 12 and 13 (but not 14).  Thus secondary amine 1 first undergoes an 
obligatory (and possibly rate-limiting) oxidation by the flavin containing momooxygenase to the 
secondary hydroxylamine 3.  The latter is further oxidized by either P450 or the FMO to form 
nitrones 5 and/or 5'.  Nitrones that can hydrolyze rapidly (possibly 5', for example) can release a 
primary hydroxylamine to be oxidized rapidly by P450 to the MIC-forming nitroso species.  
Although nitrone 5 is hydrolytically-stable, when added exogenously it is converted to an MIC 
faster much than it can hydrolyze to a primary hydroxylamine, suggesting that a non-hydrolytic 
mechanism like that of Figure 9 is required for MIC formation.  Since MI complexes are fairly 
robust their formation can also account, at least in part, for several other characteristics of P450 
inactivation by 1, such as the time-dependent loss of heme spectrum (A417) and the apparent 
covalent binding of radioactivity to microsomal protein [36, 37, 42].  The formation of ring-
opened metabolites of cyclopropylamines by P450 enzymes, and their role in inactivation of 
P450 activity, remains an open question and is the subject of ongoing work in our laboratory. 
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Table 1.  Kinetic constants for inactivation of aminopyrine N-demethylase activity in PB-
microsomes by 1 and 2. 
 
Rate constant, units 1 2 
kinact , min-1 0.049 0.027 
Ki , µM 165 116 
kinact/Ki , M-1sec-1 4.92 3.88 
n, (r2)a 5, (0.9569) 4, (0.9718) 
 
a Number of data points (observed rates) used in replot, and square of the regression coefficient 
of the replot from which the reported kinetic constants were derived. 
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Table 2.  Formation of MI complexes in microsomes and reconstituted P450 systems in vitro. 
 
 
 Percent of total P450 converted to MI complex 
 Microsomes Reconstituted P450 systems  
Compound PB UT CYP2B1 CYP2C11 CYP2E1 
1 26 20 0 0 0 
2 0 0    
3 38 36 27 30 3 
4 54 39 38 60 0 
5 28 33 6 0 0 
6 0     
7 0     
8 0     
9 0     
10 0     
11 0     
12 29     
13 8     
14 0     
15 14     
 
Blanks means experiment not done; zero means no MIC observed.  Incubation conditions were 
[P450] = 0.5 or 1.0 µM, temperature =25 ˚C, [test compound] = 100 µM.  Generally the 
maximum amount of MIC formation occurred within 15 min and remained stable for at least 30 
additional min. 
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Figure 1.  Single electron transfer (SET) mechanism for inactivation of P450 enzymes by 
cyclopropylamine 1. 
 
 
 
 
Figure 2.  Structures and numbering of compounds studied or mentioned in the text. 
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Figure 3.  Kinetics of inactivation of microsomal aminopyrine N-demethylase by 1 at 33 ˚C. 
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Figure 4.  Time course of spectral changes during oxidation of 1 at 25 ˚C by PB-microsomes 
(panel A) and their reversal by ferrricyanide (panel B).  In panel A the spectrum was scanned 
every 2 min for 30 min.  After the last spectrum of panel A was recorded sodium ferricyanide 
was added to a concentration of 50 µM and the scan shown in panel B was taken. 
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Figure 5.  (A) Rate of formation of MI complexes by 1 and related N-oxidized compounds.  PB-
microsomes, [P450]  = 1 µM, were incubated at 25 ˚C with test compounds (100 µM) and 
NADPH (1 mM) as described in Materials and Methods.  Progress curves are numbered to 
correspond to individual test compounds (see Figure 2).  (B) Rate of formation of MI complexes 
by 1 and methylated congeners.  PB-microsomes, [P450] = 3 µM, were incubated at 25 ˚C with 
test compounds (100 µM) and NADPH (1 mM) as described in Materials and Methods.  Progress 
curves are numbered to correspond to individual test compounds (see Figure 2). 
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Figure 6. Kinetics of inactivation of microsomal aminopyrine N-demethylase by different 
concentrations of oxime 2 at 33 ˚C. 
 
 
 
Figure 7.  Potential pathways and intermediates in the six-electron oxidation of secondary amines 
to oximes and MI complexes. 
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Figure 8.  Overall scheme for microsomal metabolism of N-benzyl-N-cyclopropylamine (1). 
 
 
 
 
 
 
Figure 9.  Proposed mechanism for oxidation of nitrone 5 to a nitroso intermediate for oxime 
formation and MIC formation.  
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